Phase 2 Multicenter Study of the EZH2 Inhibitor Tazemetostat as Monotherapy in Adults With Relapsed or Refractory Malignant Mesothelioma With BAP1 Inactivation (NCT02860286)

Marjorie G. Zauderer1, Peter Szlosarek2, Sylvestre Le Moulec3, Sanjay Popat3, Paul Taylor2, David Planchard4, Arnaud Scherpereel4, Thierry Jahann5, Marianna Koczywas6, Martin Forster7, Robert B. Cameron8, Tobias Peiker8, Carly Campbell8, Inbal Sapi9, Alice McDonald10, Coreen Oei11, Alicia clawson11, Maria Roche11, Dean A. Fennell11


BAP1 expression in Malignant Mesothelioma

**Figure 1A. BAP1 inactivation, as determined by immunohistochemistry.**

**Table 1. Disease characteristics by BAP1 expression.**

**Table 2. Patient disposition.**

**Table 3. Patient disposition by subset.**

**Table 4. TEAEs occurring in ≥10% of patients, regardless of relationship to study drug.**

**Figure 2. CONSORT diagram.**

**Figure 3. Summary of disease control in patients with relapsed or refractory MM.**

**Figure 4. ECOG-2003 study design.**

**Figure 5. ECOG-2003 survival analysis.**

**REFERENCES**


**CONCLUSIONS AND NEXT STEPS**

- **Tazemetostat was generally well tolerated in patients with relapsed refractory MM.**
- **Tazemetostat monotherapy showed promising anti-tumor activity in patients with tumors harboring BAP1 inactivation, including confirmed responses and long-term disease control.**
- **Further clinical evaluation of tazemetostat in combination studies is warranted.**

**ACKNOWLEDGMENTS**

- The authors thank the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.
- The authors thank all of the physicians, study coordinators, site investigators, and study coordinators for their contributions in the conduct of this study.